Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-25
2000-04-04
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31425
Patent
active
06046223&
ABSTRACT:
There is disclosed a method for treating and/or preventing macular edema and age-related macular degeneration which comprises topical administration of carbonic anhydrase inhibitors to the eye.
REFERENCES:
Wilkerson et al.--Arch Ophthalmol/vol. 11, Oct. 1993--Four-week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor.
Y. Kitazawa et al.--Journal of Glaucoma 3275-279--Dorzolamide, A topical Carbonic Anhydrase Inhibitor: A Two-Week Dose-Response Study in Patients with Glaucoma or Ocular Hypertension.
J. Messerli--Schweiz Med. Wochenschr., Vo. 123, No. 16, 1993, pp. 783-788--Akuter Visusverlust infolge okularer Durchblutungsstorunge.
Ghiou et al.--Journal of Ocular Pharmacology--vol. 9, No. 1, 1993--Effects of Antiglaucoma Drugs on Ocular Blood Flow in Ocular Hypertensive Rabbits.
Rassam et al.--Eye (1993) 7,697-702--The Effect of Acetazolamide on the Retinal Circulation.
Farber et al.--Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study--British Journal of Ophthalmology 1994; 78: 4-7.
Fishman et al.--Rebound of Macular Edema With Continue Use of Methazolamide in Patients with Retinitis Pigmentosa111, Dec. 1993, p. 1640-1646.
E-Mail from Amon to Oschmann--dated Jan. 15, 1996.
E-Mail from Amon to Korsen--dated Jan. 18, 1996.
E-Mail from Korsen to Amon--dated Jan. 18, 1996.
E-Mail from Amon to Korsen--dated Jan. 18, 1996.
E-Mail from Amon to Daniel and Korsen--dated Jan. 22, 1996.
E-Mail from Treloar to Ammon--dated Feb. 5, 1996.
E-Mail from Amon to Botelho--dated Feb. 5, 1996.
Statement of Amon accompanying Complaint filed by Sponsel against Merck--dated Feb. 10, 1997.
Statement of Vogel accompanying Complaint filed by Sponsel against Merck--dated Feb. 10, 1997.
Harris Alon
Sponsel William Eric
Advanced Research & Technology Institute
Fay Zohreh
LandOfFree
Treatment of macular edema does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of macular edema, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of macular edema will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365701